Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

IMbrave 050: A Phase III Trial of Atezolizumab Plus Bevacizumab in High-Risk Hepatocellular Carcinoma after Curative Resection or Ablation
Stephen P. Hack, Jessica Spahn, Minshan Chen, et al.
Future Oncology (2020) Vol. 16, Iss. 15, pp. 975-989
Open Access | Times Cited: 182

Showing 1-25 of 182 citing articles:

Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma
Jiao Feng, Jingjing Li, Liwei Wu, et al.
Journal of Experimental & Clinical Cancer Research (2020) Vol. 39, Iss. 1
Open Access | Times Cited: 474
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
Shukui Qin, Minshan Chen, Ann‐Lii Cheng, et al.
The Lancet (2023) Vol. 402, Iss. 10415, pp. 1835-1847
Closed Access | Times Cited: 244
Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities
Stephen P. Hack, Andrew X. Zhu, Yulei Wang
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 203
Angiogenesis as a hallmark of solid tumors - clinical perspectives
Jamal Majidpoor, Keywan Mortezaee
Cellular Oncology (2021) Vol. 44, Iss. 4, pp. 715-737
Closed Access | Times Cited: 192
Emerging immunotherapy for HCC: A guide for hepatologists
Friedrich Foerster, Simon Johannes Gairing, Sumera I. Ilyas, et al.
Hepatology (2022) Vol. 75, Iss. 6, pp. 1604-1626
Open Access | Times Cited: 168
Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology
Qinghe Zeng, Christophe Klein, Stefano Caruso, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 1, pp. 116-127
Open Access | Times Cited: 75
Increasing cure rates of solid tumors by immune checkpoint inhibitors
Weijie Ma, Ruobing Xue, Zheng Zhu, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 65
Immune Checkpoint Inhibitors Combined with Targeted Therapy: The Recent Advances and Future Potentials
Bin Li, Juan Jin, Duancheng Guo, et al.
Cancers (2023) Vol. 15, Iss. 10, pp. 2858-2858
Open Access | Times Cited: 55
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
Kang Wang, Yan‐Jun Xiang, Hongming Yu, et al.
Nature Medicine (2024) Vol. 30, Iss. 3, pp. 708-715
Closed Access | Times Cited: 52
Recent advances in the management of hepatocellular carcinoma
K. Nathan Sankar, Jun Gong, Arsen Osipov, et al.
Clinical and Molecular Hepatology (2023) Vol. 30, Iss. 1, pp. 1-15
Open Access | Times Cited: 46
Targeting the tumour vasculature: from vessel destruction to promotion
Sophie Guelfi, Kairbaan Hodivala‐Dilke, Gabriele Bergers
Nature reviews. Cancer (2024) Vol. 24, Iss. 10, pp. 655-675
Closed Access | Times Cited: 26
Immune-Based Combinations for Advanced Hepatocellular Carcinoma: Shaping the Direction of First-Line Therapy
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Future Oncology (2021) Vol. 17, Iss. 7, pp. 755-757
Closed Access | Times Cited: 84
The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
Fei Cao, Yi Yang, Tongguo Si, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 68
Atezolizumab and Bevacizumab for Hepatocellular Carcinoma: Mechanism, Pharmacokinetics and Future Treatment Strategies
Xiufeng Liu, Yi Lu, Shukui Qin
Future Oncology (2021) Vol. 17, Iss. 17, pp. 2243-2256
Open Access | Times Cited: 57
Use of chemotherapy to treat hepatocellular carcinoma
Ziqi Hou, Jie Liu, Zhaoxing Jin, et al.
BioScience Trends (2022) Vol. 16, Iss. 1, pp. 31-45
Open Access | Times Cited: 56
Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma
Lei Jiang, Luan Li, Yongzhuang Liu, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 31
Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies
Justin H. Lo, Rajiv Agarwal, Laura W. Goff, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3312-3312
Open Access | Times Cited: 27
Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data
Charles‐Henri Wassmer, Sofia El Hajji, Xenofon Papazarkadas, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4574-4574
Open Access | Times Cited: 24
Small-molecule-based targeted therapy in liver cancer
Ming Yue, Yanqiu Gong, Xuewen Fu, et al.
Molecular Therapy (2024) Vol. 32, Iss. 10, pp. 3260-3287
Closed Access | Times Cited: 11
IMbrave152/SKYSCRAPER-14: a Phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma
Shreya Badhrinarayanan, Christopher Cotter, Huaqi Zhu, et al.
Future Oncology (2024) Vol. 20, Iss. 28, pp. 2049-2057
Open Access | Times Cited: 9
Spatial immune scoring system predicts hepatocellular carcinoma recurrence
Gengjie Jia, Peiqi He, Tianli Dai, et al.
Nature (2025)
Closed Access | Times Cited: 1
Intrahepatic recurrence of hepatocellular carcinoma after resection: an update
Maria Tampaki, George Papatheodoridis, Εvangelos Cholongitas
Clinical Journal of Gastroenterology (2021) Vol. 14, Iss. 3, pp. 699-713
Closed Access | Times Cited: 55
The Current Landscape of Clinical Trials for Systemic Treatment of HCC
Friedrich Foerster, Peter R. Galle
Cancers (2021) Vol. 13, Iss. 8, pp. 1962-1962
Open Access | Times Cited: 49
Clinical Implication of Circulating Tumor Cells Expressing Epithelial Mesenchymal Transition (EMT) and Cancer Stem Cell (CSC) Markers and Their Perspective in HCC: A Systematic Review
Santhasiri Orrapin, Sasimol Udomruk, Worakitti Lapisatepun, et al.
Cancers (2022) Vol. 14, Iss. 14, pp. 3373-3373
Open Access | Times Cited: 32
Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study
Le Li, Pei‐Sheng Wu, Xiumei Liang, et al.
Journal of Gastroenterology (2023) Vol. 58, Iss. 10, pp. 1043-1054
Closed Access | Times Cited: 18
Page 1 - Next Page

Scroll to top